MAPT and Alzheimer disease: The “core” biomarkers for AD include decreased CSF Aβ42, indicating cerebral amyloid deposition, and increased total tau (t-tau) and phosphorylated tau (p-tau), representing neurofibrillary pathology and neuronal injury, respectively [6].